JP2010510323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510323A5 JP2010510323A5 JP2009538506A JP2009538506A JP2010510323A5 JP 2010510323 A5 JP2010510323 A5 JP 2010510323A5 JP 2009538506 A JP2009538506 A JP 2009538506A JP 2009538506 A JP2009538506 A JP 2009538506A JP 2010510323 A5 JP2010510323 A5 JP 2010510323A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037976 chronic inflammation Diseases 0.000 claims description 18
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 18
- 230000003432 anti-folate effect Effects 0.000 claims description 11
- 229940127074 antifolate Drugs 0.000 claims description 11
- 239000004052 folic acid antagonist Substances 0.000 claims description 11
- 239000005557 antagonist Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 8
- 229960000485 methotrexate Drugs 0.000 claims description 8
- 208000004235 neutropenia Diseases 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 6
- 230000003278 mimic effect Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 101710205889 Cytochrome b562 Proteins 0.000 claims description 3
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 claims description 3
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 claims description 3
- 102000019298 Lipocalin Human genes 0.000 claims description 3
- 108050006654 Lipocalin Proteins 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical compound COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 claims description 3
- 230000003472 neutralizing effect Effects 0.000 claims description 3
- 239000000816 peptidomimetic Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 238000000034 method Methods 0.000 description 26
- 239000003814 drug Substances 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86078006P | 2006-11-21 | 2006-11-21 | |
| US60/860,780 | 2006-11-21 | ||
| US90274207P | 2007-02-21 | 2007-02-21 | |
| US60/902,742 | 2007-02-21 | ||
| PCT/US2007/085402 WO2008064321A2 (en) | 2006-11-21 | 2007-11-21 | Methods of treating chronic inflammatory diseases using a gm-csf antagonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510323A JP2010510323A (ja) | 2010-04-02 |
| JP2010510323A5 true JP2010510323A5 (enExample) | 2011-01-13 |
| JP5410293B2 JP5410293B2 (ja) | 2014-02-05 |
Family
ID=39386167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538506A Expired - Fee Related JP5410293B2 (ja) | 2006-11-21 | 2007-11-21 | Ｇｍ−ｃｓｆアンタゴニストを用いて慢性炎症性疾患を治療する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080206241A1 (enExample) |
| EP (2) | EP2101780B1 (enExample) |
| JP (1) | JP5410293B2 (enExample) |
| KR (1) | KR101517251B1 (enExample) |
| CN (2) | CN105435223A (enExample) |
| AU (1) | AU2007323541B2 (enExample) |
| BR (1) | BRPI0719109A2 (enExample) |
| CA (1) | CA2670288C (enExample) |
| EA (1) | EA200900709A1 (enExample) |
| ES (1) | ES2432173T3 (enExample) |
| IL (1) | IL198829A0 (enExample) |
| MX (1) | MX2009005398A (enExample) |
| NZ (1) | NZ598345A (enExample) |
| SG (1) | SG176503A1 (enExample) |
| WO (1) | WO2008064321A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105435223A (zh) | 2006-11-21 | 2016-03-30 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
| AU2008287426B2 (en) * | 2007-08-10 | 2014-06-26 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
| US8680019B2 (en) * | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| RU2517596C2 (ru) | 2007-11-13 | 2014-05-27 | Эвек Инк. | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С hGM-CSF, И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ |
| BRPI0907220A2 (pt) * | 2008-01-15 | 2019-02-26 | Kalobios Pharmaceuticals, Inc. | métodos de tratar distúrbios de perda óssea usando um antagonista de gm-csf |
| EP2282757B1 (en) * | 2008-04-07 | 2013-05-22 | Kalobios Pharmaceuticals, Inc. | Neutralization of gm-csf for the treatment of heart failure |
| DK2280732T3 (en) | 2008-04-28 | 2019-01-28 | Humanigen Inc | ANTIBODIES AGAINST GRANULOCYT MACROPHAG COLONY STIMULATING FACTOR |
| CN106397591A (zh) | 2008-12-22 | 2017-02-15 | 墨尔本大学 | 骨关节炎治疗 |
| AU2015224416B2 (en) * | 2008-12-22 | 2017-04-20 | The University Of Melbourne | Osteoarthritis treatment |
| ES2978209T3 (es) | 2008-12-22 | 2024-09-09 | Univ Melbourne | Tratamiento del dolor |
| WO2010093814A1 (en) * | 2009-02-11 | 2010-08-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a gm-csf antagonist |
| CN102459340A (zh) * | 2009-04-23 | 2012-05-16 | 特罗科隆科学有限公司 | 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体 |
| CN102439039A (zh) * | 2009-05-05 | 2012-05-02 | 莫佛塞斯公司 | 多发性硬化的治疗 |
| KR20140061379A (ko) * | 2011-07-06 | 2014-05-21 | 모르포시스 아게 | 항ｃｄ20 및 항ｇｍｃｓｆ 항체의 치료 조합물 및 이의 용도 |
| SG10201803778PA (en) * | 2012-09-20 | 2018-06-28 | Morphosys Ag | Treatment for rheumatoid arthritis |
| KR20210021153A (ko) * | 2012-09-20 | 2021-02-24 | 모르포시스 아게 | 류마티스 관절염에 대한 치료 |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| BR112016003293A8 (pt) * | 2013-08-30 | 2022-08-16 | Takeda Gmbh | Anticorpos neutralizantes de gm-csf para utilização no tratamento de artrite reumatoide ou como analgésicos |
| JP6360696B2 (ja) * | 2014-03-18 | 2018-07-18 | 日本光電工業株式会社 | 血液検査装置および血液検査方法 |
| US20170260276A1 (en) * | 2014-05-19 | 2017-09-14 | Medimmune Limited | Treatment for rheumatoid arthritis |
| WO2018031967A1 (en) * | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| MX2019003019A (es) * | 2016-09-19 | 2019-09-19 | I Mab | Anticuerpos anti-gm-csf y usos de los mismos. |
| CN111757744A (zh) | 2017-10-02 | 2020-10-09 | 人源股份有限公司 | 使用gm-csf拮抗剂治疗免疫疗法相关毒性的方法 |
| US11130805B2 (en) | 2017-10-02 | 2021-09-28 | Humanigen, Inc. | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |
| US10927168B2 (en) | 2017-10-02 | 2021-02-23 | Humanicen, Inc. | Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab |
| US10899831B2 (en) | 2017-10-02 | 2021-01-26 | Humanigen, Inc. | Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity |
| CA3116412A1 (en) * | 2018-10-31 | 2020-05-07 | Humanigen, Inc. | Materials and methods for treating cancer |
| AU2021235899A1 (en) * | 2020-03-08 | 2022-10-13 | Humanigen, Inc. | Methods for treating coronavirus infection and resulting inflammation-induced lung injury |
| KR20230124910A (ko) * | 2020-12-04 | 2023-08-28 | 씨에스엘 이노베이션 피티와이 엘티디 | 염증성 피부 상태 치료 방법 |
| US20240317846A1 (en) * | 2021-03-08 | 2024-09-26 | Humanigen, Inc. | Methods for treating coronavirus infection and resulting inflammation-induced lung injury |
| CN116887856A (zh) * | 2022-01-20 | 2023-10-13 | 舒泰神（北京）生物制药股份有限公司 | 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| IL95061A0 (en) * | 1989-07-14 | 1991-06-10 | Schering Corp | Antagonists of gm-csf derived from the carboxyl terminus |
| WO1994009149A1 (en) | 1990-08-10 | 1994-04-28 | Amrad Corporation Limited | Monoclonal antibody |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| WO1997029131A1 (en) | 1996-02-09 | 1997-08-14 | Basf Aktiengesellschaft | HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a) |
| US5770380A (en) | 1996-09-13 | 1998-06-23 | University Of Pittsburgh | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold |
| EP1051432B1 (en) | 1998-12-08 | 2007-01-24 | Biovation Limited | Method for reducing immunogenicity of proteins |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7108852B2 (en) * | 2000-03-20 | 2006-09-19 | Warner-Lambert Company Llc | Methods of treating inflammation using antibodies to M-CSF |
| US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
| WO2003068924A2 (en) * | 2002-02-13 | 2003-08-21 | Ludwig Institute For Cancer Research | Fusion proteins of humanized g250 specific antibodies and uses thereof |
| GB0224082D0 (en) * | 2002-10-16 | 2002-11-27 | Celltech R&D Ltd | Biological products |
| KR101294959B1 (ko) * | 2003-03-12 | 2013-08-09 | 제넨테크, 인크. | 조혈을 촉진하기 위한 ｂｖ８ 및(또는) ｅｇ-ｖｅｇｆ의 용도 |
| CA2533594C (en) * | 2003-07-23 | 2013-04-02 | Synta Pharmaceuticals, Corp. | Compounds for inflammation and immune-related uses |
| JP4782700B2 (ja) | 2004-01-20 | 2011-09-28 | カロバイオス ファーマシューティカルズ インコーポレイティッド | 最低限必須な結合決定基を用いた抗体特異性の移入 |
| CN101014329B (zh) * | 2004-07-16 | 2010-09-08 | 杏林制药株式会社 | 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物 |
| US20060134098A1 (en) | 2004-11-16 | 2006-06-22 | Kalobios, Inc. | Immunoglobulin variable region cassette exchange |
| RS53743B1 (sr) | 2005-05-18 | 2015-06-30 | Morphosys Ag | Anti-gm-csf antitela i njihova upotreba |
| WO2007082177A2 (en) * | 2006-01-06 | 2007-07-19 | Mount Sinai School Of Medicine Of New York University | Myeloid suppressor cells, methods for preparing them, and methods for using them for treating autoimmunity |
| ES2609088T3 (es) * | 2006-02-08 | 2017-04-18 | Morphotek, Inc. | Péptidos GM-CSF antigénicos y anticuerpos anti-GM-CSF |
| RU2495050C2 (ru) | 2006-03-27 | 2013-10-10 | Медимьюн Лимитед | Связующий элемент для рецептора gm-csf |
| DE102006033837A1 (de) * | 2006-07-21 | 2008-01-31 | Medac Gesellschaft für klinische Spezialpräparate m.b.H | Konzentrierte Methotrexat-Lösungen |
| CN105435223A (zh) | 2006-11-21 | 2016-03-30 | 卡罗拜奥斯制药公司 | 使用gm-csf拮抗剂治疗慢性炎症疾病的方法 |
-
2007
- 2007-11-21 CN CN201510674256.5A patent/CN105435223A/zh active Pending
- 2007-11-21 CN CNA2007800495322A patent/CN101605547A/zh active Pending
- 2007-11-21 SG SG2011085834A patent/SG176503A1/en unknown
- 2007-11-21 KR KR1020097012906A patent/KR101517251B1/ko not_active Expired - Fee Related
- 2007-11-21 WO PCT/US2007/085402 patent/WO2008064321A2/en not_active Ceased
- 2007-11-21 US US11/944,162 patent/US20080206241A1/en not_active Abandoned
- 2007-11-21 CA CA2670288A patent/CA2670288C/en not_active Expired - Fee Related
- 2007-11-21 JP JP2009538506A patent/JP5410293B2/ja not_active Expired - Fee Related
- 2007-11-21 BR BRPI0719109-0A2A patent/BRPI0719109A2/pt not_active IP Right Cessation
- 2007-11-21 EP EP07868831.4A patent/EP2101780B1/en not_active Revoked
- 2007-11-21 NZ NZ598345A patent/NZ598345A/xx not_active IP Right Cessation
- 2007-11-21 ES ES07868831T patent/ES2432173T3/es active Active
- 2007-11-21 MX MX2009005398A patent/MX2009005398A/es active IP Right Grant
- 2007-11-21 EP EP11182971A patent/EP2402013A1/en not_active Withdrawn
- 2007-11-21 AU AU2007323541A patent/AU2007323541B2/en not_active Ceased
- 2007-11-21 EA EA200900709A patent/EA200900709A1/ru unknown
-
2009
- 2009-05-19 IL IL198829A patent/IL198829A0/en unknown
-
2015
- 2015-05-14 US US14/712,627 patent/US20150246121A1/en not_active Abandoned